• Median OS was 12.3 months with TECENTRIQ + carbo/etop vs 10.3 months with placebo + carbo/etop (HR=0.70; 95% CI, 0.54, 0.91; P=0.0069) with a median follow-up of 13.9 months 1,2*

*Based on OS interim analysis.

NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. See the NCCN Guidelines® for detailed recommendations, including other preferred options.
Category 1: based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

1L=first line; carbo/etop=carboplatin/etoposide; ES-SCLC=extensive-stage small cell lung cancer; NCCN=National Comprehensive Cancer Network; OS=overall survival.